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Fetal programming as the cause of all the evils in
adult humans: atherosclerosis and coronary
heart disease included
Balistreri Carmela R.
Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of Palermo, Italy
The theory of David Barker on “the fetal origin of adult
diseases” is revolutionising the pathophysiology and ae-
tiopathogenesis of adult human diseases such as ath-
erosclerosis. Atherosclerosis and related coronary heart
diseases (CHDs) appear to be the result of fetal program-
ming, with the cardiovascular system, and particularly the
endothelium component, being the principal target of this
process. This suggests that cardiovascular diseases can
take place during fetal development. This life period is cru-
cial for developmentally programming body systems (such
as the cardiovascular system), their ageing and disease. A
sophisticated interplay of exogenous-gestational environ-
mental factors with the fetal genome induces epigenetic
changes (microRNA, DNA methylation patterns and his-
tone structure alterations) and expression of altered phe-
notypes of developing systems. A poor maternal diet rich
in cholesterol, diabetes, obesity, smoking and exposure to
various environmental pollutants represent the major fac-
tors related to an increased risk and progression of ath-
erosclerosis in postnatal life. The fetal cardiovascular sys-
tem is susceptible to these factors, and developmental
programming events cause endothelial dysfunction, small
coronary arteries, stiffer vascular tree, fewer cardiomy-
ocytes, coagulopathies and atherogenic blood lipid pro-
files in the fetus. Consequently, preventive interventions
are recommended for both parents who want to have chil-
dren, for counteracting the onset of atherosclerosis and
CHDs in new generations.
Keywords: developmental programming, fetal cardiovas-
cular development, endothelial dysfunction
Introduction
For many decades, researchers have focussed their interest
and efforts on identifying the mechanisms involved in the
complex pathophysiology of atherosclerosis and its com-
mon complications, such as coronary heart diseases
(CHDs). Thanks to modern treatments, such as new throm-
bolysis and percutaneous coronary intervention proce-
dures, CHDs show a significant reduction in incidence [1].
In addition, the intense experimental investigation in both
animal models and humans has allowed the discovery of
mechanisms and pathways involved in the pathophysiolo-
gy of atherosclerosis and, thereby, to attribute it to diverse
processes [2]. Accordingly, the first process was choles-
terol storage, since accumulation of cholesterol and throm-
botic debris in the artery wall, and more precisely in the
intima, has been shown to be a crucial mechanism. Sub-
sequently (during the time between the 1960s and 1970s),
a typical mechanism in arterial pathology was found to be
the proliferation of smooth-muscle cells in atherosclerot-
ic plaques [2]. Today, it is considered to be a multistep
chronic inflammatory disease, because inflammation rep-
resents the primary mechanism [2]. Well-established evi-
dence supports this, indicating the inflammatory molecu-
lar and cellular pathways involved [3, 4]. These last release
into the vascular microenvironment mediators able to alter
arterial structure and function, and promote atherothrom-
botic events at a systemic level [5]. The best-studied innate
inflammatory pathways are the Toll-like receptors (TLRs),
particularly the TLR-4 and TLR-2, which have been and
are an object of research in atherosclerosis investigations
[6, 7]. Accordingly, their crucial role has been demonstrat-
ed, particularly of the TLR-4, in driving the pathway net-
works involved in the complex pathophysiology of both
atherosclerosis and CHDs [6, 7], as well as in myocardial
infarction as demonstrated by our group [8, 9].
The crucial relevance of inflammation in the onset of ath-
erosclerosis also derives from its role as an independent
mechanism in the condition of allograft arteriosclerosis
(widely quoted in [2]). These data emphasise that inflam-
mation per se, without traditional risk factors, can deter-
mine arterial hyperplasia. Today, in the era of the modern
medicine, including precision and regenerative medicine
and the biotechnologies of the last generation, the modu-
lation of inflammatory pathways, for example via TLR-4,
can influence the onset of atherosclerosis in experimental
models [10, 11]. Validation of these results in humans and
their clinical application is ongoing. In addition, these con-
cepts reduce the importance of risk factors as causal fac-
tors. This leads to the consideration that inflammation is a
“tool” that mechanistically connects alterations induced by
traditional risk factors with changes in the vascular (artery)
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wall related to onset of atherosclerosis and its complica-
tions, such CHDs
Evidence on the central role of inflammation in the patho-
physiology of atherosclerosis is leading to a search for its
primordial origins in the early stages of the life of an in-
dividual, since Dr Barker proposed the theory “of the fe-
tal origin of adult diseases” [12]. Recent findings suggest
that atherosclerosis is the result of the “fetal programming
process”, which governs the development of body systems
and sets their ageing and disease (such as atherosclerosis)
in adult life. Here, a concise overview of recent evidence
in this field is reported and discussed, with the hope to pro-
vide additional knowledge on the mechanisms and path-
ways involved, and to confirm their inflammatory basis in
order to suggest potential interventions.
Does atherosclerosis origin from fetal develop-
mental programming?
Based on Dr Barker’s theory on the fetal origin of adult
diseases [12], today the origin of the major age-related dis-
orders (ARDs) of new progeny may be attributed to devel-
opmental processes occurring during embryonic, fetal and
early postnatal life. This supports the view that the clini-
cal problems of both parents and the exposures to external
influences during the intrauterine/perinatal life of each Eu-
therian mammal, humans included, can permanently mod-
ulate the structure and functionality of specific body sys-
tems, such as the cardiovascular system, predisposing them
to ARDs such as atherosclerosis and CHD. Established ev-
idence supports these concepts. It has been reported that
new progenies born after intrauterine growth restriction
(IUGR) show an augmented risk of perinatal morbidity/
mortality, and those who survive have long-term conse-
quences, specifically a high susceptibility to developing
systemic hypertension, atherosclerosis, CHD and chronic
kidney disease [13]. Hyperactivity of the hypothalamic-pi-
tuitary-adrenal axis, systemic inflammation, and early al-
terations in vascular structure and function have, indeed,
been detected in IUGR new-borns [14]. Furthermore, ma-
ternal hypercholesterolaemia during pregnancy has been
associated with augmented fatty streak formation in human
fetal arteries and accelerated progression of atherosclerosis
during childhood. Consistent with this, data from recent
investigations in genetically more homogeneous rabbits
subjected to temporary diet-induced maternal hypercholes-
terolaemia provide evidence that this condition induces in
the offspring postnatal atherogenesis in response to the hy-
percholesterolaemia. Maternal treatments with cholesterol-
lowering agents or antioxidants have been demonstrated
to decrease fetal and postnatal atherogenesis [15]. Another
study, using an apoE mouse model, demonstrated a strong
effect of fetal programming on the development of ather-
osclerosis [16]. Other studies report that fetal exposure to
high cholesterol, diabetes and maternal obesity is signif-
icantly associated with increased risk and progression of
atherosclerosis in new-borns (amply quoted in [17, 18])
In addition, some studies have shown a relevant role of
epigenomic mechanisms in the transgenerational transmis-
sion of programmed obesity and metabolic syndrome, as
recently reviewed by Desai and colleagues [18].
The endothelium as the key target of fetal pro-
gramming
Evidence has demonstrated that endothelium is the major
target of fetal programming. Its modifications leading to
dysfunction have been shown to primarily derive from ad-
verse parental and fetal environmental conditions. In sup-
port of this evidence, it has been found that levels of the
crucial molecules involved in the physiological maturation
and differentiation of fetal endothelium (vascular endothe-
lial derived growth factor [VEDGF], its receptors and tran-
scription factors) are affected by several adverse condi-
tions, such as chronic hypoxia, maternal food restriction,
altered levels of glucocorticoids and microRNA [19]. In
addition, other studies have shown how chronic hypoxia
and altered maternal clinical conditions impact the matu-
ration and differentiation of endothelium and the vascula-
ture of all the tissues, ranging from feto-placental arteries,
carotid arteries and myocardium, to the cerebrovascular
system and renal, liver and pulmonary arteries [20–22].
Another study also reported that the IUGR condition in
rats affects the function of both endothelium cells and their
progenitors [23, 24]. The relevance of this evidence is par-
ticularly stressed by Musa and co-workers [25]. They have
recently reviewed the data, from about 230 studies, on the
key role of maternal and intrauterine conditions on en-
dothelium structure and function in the offspring, by re-
porting all the related alterations mechanisms and path-
ways involved.
Furthermore, an investigation published in 2018 and con-
ducted in equine embryos has shown that maternal obesity
induces long-term effects in offspring, predisposing them
to obesity and metabolic syndrome [26]. Similar data have
been obtained from a study conducted in the transgenic
apoE*3 Leiden mouse [27]. Specifically, the impact of ma-
ternal consumption of dietary partially hydrogenated veg-
etable oil (PHVO; P), and ruminant milk fat (R) on the
development of atherosclerosis in their offspring has been
investigated [27]. Data obtained demonstrated that there is
a significant effect of maternal diet during pregnancy on
the development of atherosclerosis in the offspring, and
particularly in new-borns born from mothers fed R or P
diet during pregnancy [27]. In addition, the group of Dr
Martino reported that epigenetic factors have a key role in
determining these effects in offspring and may be used as
biomarkers for early detection of children at risk and as tar-
gets for developing new therapies [17].
Based on this evidence, endothelium appears to be the key
target of fetal programming, and this determines its suscep-
tibility to develop dysfunction, conditions related to many
human pathologies, not only of the cardiovascular system
such as ARDs and, indeed, essentially linked to the ageing
process [28–31].
Furthermore, the key role of inflammation as key deter-
minant of programmed atherosclerosis in new-borns is
emerging, as reported in next section.
Inflammation as key determinant of pro-
grammed atherosclerosis in newborns
Given the well-recognised role of inflammation in the on-
set of CVDs such as atherosclerosis and CHDs, its im-
portance in offspring that have experienced prenatal in-
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Figure 1: All the factors recognised to modulate foetal programming that determines an increased activation of hypothalamic-pituitary-adrenal
axis and consequently sustained inflammation. These mechanisms both impact through epigenetic factors the expression of cardiovascular
phenotypes that lead to long-term alterations in structure and function of endothelium, modulating its subsequent functioning in neonatal and
adulthood periods provoking dysfunction, contributing to small coronary arteries, stiffer vascular tree, fewer cardiomyocytes, coagulopathies
and atherogenic blood lipid profiles. All these adverse conditions significantly will increase the susceptibility to onset of atherosclerosis and
coronary heart diseases.
flammation exposure (PIE) has also been investigated.
Specifically, it has been demonstrated that maternal in-
fluenza exposure and febrile genitourinary infections affect
fetal cardiovascular development, predisposing the proge-
ny to CVDs such as atherosclerosis [32–36]. Similar data
have been obtained by investigating maternal pre-pregnan-
cy obesity and diabetes, and excessive gestational weight
gain. Specifically, under these maternal conditions an in-
creased activation of inflammatory pathways and a sus-
tained macrophage infiltration in the placenta has been
detected [37–40]. Furthermore, early onset of maternal
higher blood pressure or preeclampsia during pregnancy
have been associated with a sustained response of inflam-
matory CD4+ T cell subsets, accompanied by higher plas-
ma levels of interleukin-6 (IL-6), IL-17 and tumour necro-
sis factor (TNF)-α in mothers [41]. In addition, it has been
demonstrated that maternal hypertension can affect early
childhood blood pressures and cardiovascular health in
the offspring [42, 43]. Maternal smoking has been also
demonstrated to cause a proinflammatory state, including
elevated maternal serum levels of TNF-α and IL-1β, that
is recognised as an independent risk factor for CVDs
[44–46]. This sustained inflammation has been also
demonstrated to be the result of the crosstalk among in-
flammatory pathways (such as TLR-4), oxidative stress,
over-activation of the renin-angiotensin system (RAS),
NF-κB (nuclear factor “kappa-light-chain-enhancer” of ac-
tivated B cells) deregulated homeostasis, epigenetic repro-
graming, and dysregulation of the immune system and the
hypothalamic-pituitary-adrenal axis [47]. This evidence
has been recently stressed by Deng and co-workers in
a well-structured review [47]. Moreover, oral administra-
tion with pyrrolidine dithio-carbamate (PDTC), a potent
antioxidant, in the second pregnancy trimester has been
shown to effectively prevent PIE-programmed hyperten-
sion, vascular damage [48] and myocardial remodelling
[49] in rats. In addition, early postnatal treatment with
PDTC, N-acetyl-l-cysteine (NAC), a glutathione precur-
sor, or Tempol, a superoxide dismutase-mimetic drug, has
been found to prevent PIE-programmed CVDs in animal
models [48]. Consequently, treatments against inflamma-
tion, oxidative stress, etc. in prenatal and early postnatal
life might be appropriate therapeutic methods for the pre-
vention of PIE-CVDs.
Conclusions and perspectives
Mounting evidence from epidemiological, clinical and ex-
perimental studies has clearly shown a close association
between developmental adversity in utero and an augment-
ed risk of diverse diseases, such as atherosclerosis, in later
life [12]. Fetal stressors such as hypoxia, infections, mal-
nutrition, obesity and fetal exposure to nicotine, alcohol,
cocaine and glucocorticoids may directly or indirectly im-
pact cardiovascular programming, by inducing a sustained
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Figure 2: Some interventions and therapeutic approaches that might reduce the inflammatory status responsible for the altered programming
of the cardiovascular system, and recommendations for modifying the diet, performing physical exercise and adopting interventions on the gut
microbiome in both parents before and during gestation, and in neonatal and adult life of new-borns, are also suggested.
inflammation and activation of hypothalamic-pituitary-
adrenal axis, alterations to cellular and molecular levels
of cardiovascular system, with the result of programming
the endothelium and the susceptibility to onset of diverse
pathologies, such as atherosclerosis [8] (figure 1). The fun-
damental mechanisms and pathways are not completely
recognised. However, the role of inflammation and epige-
netic mechanisms on developing endothelium appears to
be very relevant [9]. Consequently, pharmacological ma-
nipulations of both inflammation and epigenetic mecha-
nisms in the second pregnancy trimester might represent
promising interventional strategies. Accordingly, several
experimental studies in animals show promising data based
on the use of DNA methylation inhibitors and other agents,
such as plant-derived isoflavone-genistein, leptin, folate,
fish oil, omega-3 and vitamin D (figure 2). These treat-
ments can modify the corresponding abnormal epigenetic
alternations and ameliorate the adverse programming ef-
fects caused by prenatal stress [50]. Helpful effects have
been also obtained modifying diet, physical exercise and
performing interventions on the gut microbiome [51, 52].
Scrupulous studies are essential to advance our knowledge
in this field and to develop appropriate treatments, such as
prenatal or postnatal supplementations.
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